Christine Boisclair - Concert Pharmaceuticals Vice President - Regulatory Affairs
| CNCEDelisted Stock | USD 8.37 0.01 0.12% |
President
Ms. Christine Boisclair is the Vice President Regulatory Affairs of the Company. Ms. Boisclair joins Concert with more than 30 years of regulatory affairs experience in the biopharmaceutical industry across multiple therapeutic areas. Prior to joining Concert, Ms. Boisclair was Vice President, Regulatory Affairs, at Forum Pharmaceuticals. Before joining Forum Pharmaceuticals, she held management roles at several companies including Insmed, Agennix, OSI Pharmaceuticals, Genzyme Corporationrationration, Immulogic Pharmaceuticals and Parexel International since 2016.
| Tenure | 8 years |
| Phone | 781 860 0045 |
| Web | https://www.concertpharma.com |
Concert Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3853) % which means that it has lost $0.3853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0868) %, meaning that it created substantial loss on money invested by shareholders. Concert Pharmaceuticals' management efficiency ratios could be used to measure how well Concert Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Concert Pharmaceuticals currently holds 14.51 M in liabilities with Debt to Equity (D/E) ratio of 0.11, which may suggest the company is not taking enough advantage from borrowing. Concert Pharmaceuticals has a current ratio of 9.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Concert Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Juan Garcia | Meli Hotels International | N/A | |
| Tony Moralejo | Dine Brands Global | 59 | |
| Gabriel Picornell | Meli Hotels International | N/A | |
| Mark Hoddinott | Meli Hotels International | N/A | |
| Arthur Suazo | Hudson Pacific Properties | 59 | |
| Andy Wattula | Hudson Pacific Properties | 48 | |
| Carl Mayfield | Park Hotels Resorts | 60 | |
| Laura Campbell | Hudson Pacific Properties | N/A | |
| Bryan Adel | Dine Brands Global | 57 | |
| Christopher Barton | Hudson Pacific Properties | 54 | |
| Fernando Mulet | Playa Hotels Resorts | 48 | |
| Allison Hall | Dine Brands Global | 59 | |
| Steven Jaffe | Hudson Pacific Properties | 58 | |
| Pilar Company | Meli Hotels International | N/A | |
| John Florsheim | Weyco Group | 60 | |
| Drew Gordon | Hudson Pacific Properties | 57 | |
| Jay Johns | Dine Brands Global | 63 | |
| Kay Tidwell | Hudson Pacific Properties | 47 | |
| Joshua Hatfield | Hudson Pacific Properties | 46 | |
| Sean DellOrto | Park Hotels Resorts | 49 | |
| John Cywinski | Dine Brands Global | 61 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 |
Concert Pharmaceuticals Leadership Team
Elected by the shareholders, the Concert Pharmaceuticals' board of directors comprises two types of representatives: Concert Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Concert. The board's role is to monitor Concert Pharmaceuticals' management team and ensure that shareholders' interests are well served. Concert Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Concert Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nancy Stuart, Chief Officer | ||
| James Cassella, Senior Vice President chief development officer | ||
| Marc Becker, Chief Officer | ||
| Christine Boisclair, Vice President - Regulatory Affairs | ||
| Justine Koenigsberg, VP of Corporate Communications and Investor Relations | ||
| Jeffrey Munsie, Chief Sec | ||
| Nabil PharmD, VP Devel | ||
| Roger Tung, Co-Founder, CEO and President and Director | ||
| Mba MBA, CoFounder Chairman |
Concert Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Concert Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 86.63 M | |||
| Shares Outstanding | 48.02 M | |||
| Shares Owned By Insiders | 3.77 % | |||
| Shares Owned By Institutions | 77.05 % | |||
| Number Of Shares Shorted | 1.08 M | |||
| Price To Earning | 3.08 X | |||
| Price To Book | 1.67 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Concert Stock
If you are still planning to invest in Concert Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Concert Pharmaceuticals' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |